Key result
sICD plus metoprolol and disopyramide reduces outflow gradient and resolves symptoms in massive septal hypertrophy.
Why the study?
Hypertrophic cardiomyopathy is the most common genetic cardiovascular disorder with an extremely variable clinical presentation, highlighting the need to explore presentation and prognostic assessment in massive forms.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the role of multimodality imaging, particularly cardiac magnetic resonance, in the prognostic assessment and management of massive hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disorder and it has an extremely variable clinical presentation. Here we report the case of a young patient, with no previous cardiac history or cardiovascular risk factors, presenting to the emergency department with chest pain, electrocardiographic changes, and troponin elevation. The diagnosis of hypertrophic cardiomyopathy was immediate following echocardiographic evidence of a massive form of left ventricular septal hypertrophy (44 mm), leading to left ventricular outflow tract obstruction with a dynamic gradient (Figure 1). Characterization of the clinical picture and prognostic risk was further expanded by cardiac magnetic resonance imaging, in particular through tissue characterization (Figure 2), which allowed the identification of diffuse fibrosis through native T1 mapping, edema through T2 mapping, and extensive non–ischemic intramyocardial replacement fibrosis with late gadolinium enhancement (Figure 3). Given the patient’s young age, the extensive fibrosis on magnetic resonance imaging, and the documentation of episodes of non–sustained ventricular tachycardia on telemetry monitoring, the patient underwent implantation of an sICD for primary prevention due to a high risk of sudden cardiac death according to both European and American guidelines. A genetic analysis was also performed, revealing pathogenic mutations in the sarcomeric genes MYBPC3 and TNNT2. Subsequent echocardiographic follow–up showed a progressive reduction of the intraventricular outflow tract gradient thanks to medical therapy with metoprolol and disopyramide, as well as an almost complete resolution of the patient’s symptoms. This clinical case is therefore particularly noteworthy because of the echocardiographic and magnetic resonance presentation and opens the discussion on the role of the latter in the prognostic assessment of the disease.
No takes yet. Share an insight, caveat, or question.
Baù et al. (2026) conducted a case report in Hypertrophic cardiomyopathy (n=1). sICD implantation and medical therapy (metoprolol and disopyramide) was evaluated. In a young patient with massive septal hypertrophy, sICD implantation and medical therapy with metoprolol and disopyramide led to outflow tract gradient reduction and symptom resolution.
Synapse has enriched 10 related papers. Consider them for comparative context: